Long-term effects of spironolactone in peritoneal dialysis patients

Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Hirofumi Tamai, Takeyuki Hiramatsu, Hiroshige Ohashi, Isao Ito, Hirotake Kasuga, Masanobu Horie, Shoichi Maruyama, Yukio Yuzawa, Tatsuaki Matsubara, Seiichi Matsuo, M. Watanabe, H. Nishimura, M. Mizutani, H. Kinashi, A. Dambara, Y. Saka, S. TodaS. Kimu, K. Minoshima, M. Yamaha, R. Takahashi, K. Kimura, T. Naruse, T. Matsuoka, D. Inaguma, K. Kurata

研究成果: Article

55 引用 (Scopus)

抜粋

ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to highmortality.Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

元の言語English
ページ(範囲)1094-1102
ページ数9
ジャーナルJournal of the American Society of Nephrology
25
発行部数5
DOI
出版物ステータスPublished - 01-05-2014

All Science Journal Classification (ASJC) codes

  • Nephrology

フィンガープリント Long-term effects of spironolactone in peritoneal dialysis patients' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Ito, Y., Mizuno, M., Suzuki, Y., Tamai, H., Hiramatsu, T., Ohashi, H., Ito, I., Kasuga, H., Horie, M., Maruyama, S., Yuzawa, Y., Matsubara, T., Matsuo, S., Watanabe, M., Nishimura, H., Mizutani, M., Kinashi, H., Dambara, A., Saka, Y., ... Kurata, K. (2014). Long-term effects of spironolactone in peritoneal dialysis patients. Journal of the American Society of Nephrology, 25(5), 1094-1102. https://doi.org/10.1681/ASN.2013030273